Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DV3316 Pen-injector vs FlexPen in Diabetes
NCT02627287Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2015
- Primary completion
- Feb 2016
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial (2 arms), sponsored by Novo Nordisk. Primary endpoint: Injection success (full dose delivered s.c.) at Day 1. Started Dec 2015; status: completed.
Beyond the preview
Go deeper on NCT02627287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02627287.